Cancer Drug Safety and Public Health Policy

Chapter 1 Fluoroquinolone-Associated Disability and Other Fluoroquinolone-Associated Serious Adverse Events: Unexpected Toxicities Have Emerged in Recent Years

Chapter 2 Biosimilar Epoetin in the United States: A View from the Southern Network on Adverse Reactions

Chapter 3 Policing of Drug Safety Information Dissemination Under the False Claims Act

Chapter 4 Translating Research into Health Policy: The Citizen Petition Experience with the Food and Drug Administration

Chapter 5 Systemic Barriers and Potential Concerns from Reporting Serious Adverse Drug Reactions

Chapter 6 Was There Something Rotten in Denmark: Nephrogenic System Fibrosis Cases Occurring in Copenhagen

Chapter 7 Rituximab-Associated Progressive Multifocal Leukoencephalopathy: A Twenty-Year Update

Chapter 8 Maximum Accuracy Machine Learning Statistical Analysis—A Novel Approach

Chapter 9 Investigating Severe Adverse Reactions: Examples of the ANTICIPATE Methodology at Work

Chapter 10 Consequences to Patients, Clinicians, and Manufacturers When Very Serious Adverse Drug Reactions Are Identified (1997–2019): A Qualitative Analysis from the Southern Network on Adverse Reactions (SONAR)

Chapter 11 Moderna, Pfizer-BioNTech, and Johnson & Johnson/Janssen Post-Covid Vaccine Hematological Adverse Events Including Cerebral Venous Sinus Thrombosis (CVST), Thrombotic Thrombocytopenia (VITT), Blood Clots, Increased Vaginal/Menstrual Bleeding and/or Miscarriage, Stillbirth Delivery, or Premature Birth

Chapter 12 Investigating Novel Genetic Markers for Fluoroquinolone Associated Disorders